GLPwatch

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

NCT07221214 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a medication called a GLP-1 receptor agonist can help people living with HIV who drink alcohol and smoke reduce their weekly alcohol consumption over a 3-month period.

Status Recruiting Currently enrolling participants.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 200 people Planned (estimated).
Who can join Ages 18–89 · all sexes
Timeline Started 2026-04 · est. completion 2030-01
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07221214 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are: 1. Does semaglutide lower the average number of alcoholic beverages participants drink per week? 2. Does semaglutide lower the average number of cigarettes participants smoke per day? 3. Does semaglutide decrease the risk for cardiovascular disease among people living with HIV who drink alcohol and/or smoke tobacco? Researchers will compare the effects of semaglutide to a placebo (a look-alike substance that contains no drug) to see if semaglutide works to lower the alcohol intake among participants each week. Participants will: 1. Take semaglutide for 3 months 2. Visit the research clinic 3 times for checkups and tests 3. Provide blood samples, stool samples, and saliva samples for tests.

Treatments tested

Main thing measuredAverage drinks/week past 30 days at 3 months
SponsorVanderbilt University Medical Center
Conditions studiedHIV, Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention
GLP-1 drugs —

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07221214 ↗